64 search results for: symposium

ADVENT at EAACI 2025
Congress
13
June
2025
Congress
ADVENT at EAACI 2025

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

ADVENT at ERS-ISIAN 2025
Congress
20
June
2025
Congress
ADVENT at ERS-ISIAN 2025

Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.

.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT at NAPNAP 2025
Congress
12
March
2025
Congress
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
Dermatology
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
expert video

This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

View more
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dermatology
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
expert video

Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP

View more
ADVENT at ERS 2024
Congress
7
September
2024
Congress
ADVENT at ERS 2024

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

ADVENT at EADV 2024
Congress
25
September
2024
Congress
ADVENT at EADV 2024

Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.

 

UEG 2026 Symposium Thumbnail
Congress
17
October
2026
Congress
ADVENT at UEG Week 2026

Sit down with three leading experts—Professors David Rubin, MD; Evan Dellon, MD, MPH; and Thomas Greuter, MD—for a patient case–based roundtable discussion bringing together inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) perspectives on progression and esophageal remodeling in EoE.

How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
On Demand
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

ESPGHAN 2025
On Demand
Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients

Pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.

AANP Symposium Thumbnail
On Demand
Coughing, Choking, Wheezing, Itching, Sneezing: Understanding the Connection Between Atopic Diseases Through a Case-Based Panel of Expert Nurse Practitioners

Join leading experts Miguel Lanz, Lakshi Aldredge, Angela Bretton, and Hilary Ugras in an engaging case-based discussion that explores the interconnected nature of chronic underlying type 2 inflammation and its profound impact across multiple diseases.